Literature DB >> 22845611

Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?

Jonathan M Payne1, Shelley S Arnold, Natalie A Pride, Kathryn N North.   

Abstract

AIM: Although approximately 40% of children with neurofibromatosis type 1 (NF1) meet diagnostic criteria for attention-deficit-hyperactivity disorder (ADHD), the impact of ADHD on the executive functioning of children with NF1 is not understood. We investigated whether spatial working memory and response inhibition are impaired in children with NF1 without a diagnosis of ADHD and whether executive deficits are exacerbated in children with a comorbid diagnosis.
METHOD: Forty-nine children aged 7 to 15 years with NF1 only (31 males, 18 females; mean age 11y, SD 2y 4mo) or 35 with NF1 and ADHD (18 males, 17 females; mean age 10y 8mo, SD 2y 4mo) and 30 typically developing comparison children (16 males, 14 females; mean age 10y, SD 2y 8mo) were compared on measures of spatial working memory and response inhibition. Group differences in IQ and visuospatial ability were controlled for as required.
RESULTS: Compared with typically developing children, children with NF1 with or without comorbid ADHD demonstrated significant impairment of both spatial working memory (both p<0.004) and inhibitory control (both p<0.010). There were, however, no differences between the two NF1 groups in spatial working memory (p=0.91) or response inhibition (p=0.78).
INTERPRETATION: Executive dysfunction occurs with the same severity in children with NF1, whether or not they have a comorbid diagnosis of ADHD, suggesting that executive impairments are not unique contributors to ADHD symptomatology in NF1. The findings are discussed within the context of recent evidence in Nf1 optic glioma (OPG) mice, in which a mechanistic connection between NF1 gene expression, executive system failure, and dopaminergic pathway integrity has been established. © The Authors. Developmental Medicine & Child Neurology
© 2012 Mac Keith Press.

Entities:  

Mesh:

Year:  2012        PMID: 22845611     DOI: 10.1111/j.1469-8749.2012.04357.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

Review 1.  A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1.

Authors:  Andrew J D Crow; Jennica M Janssen; Carolina Marshall; Anne Moffit; Laura Brennan; Christian G Kohler; David R Roalf; Paul J Moberg
Journal:  Am J Med Genet A       Date:  2022-05-12       Impact factor: 2.578

Review 2.  An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.

Authors:  Taylor F Smith; Jessica A Kaczorowski; Maria T Acosta
Journal:  Childs Nerv Syst       Date:  2020-07-03       Impact factor: 1.475

Review 3.  Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1.

Authors:  Martha Milade Torres Nupan; Alberto Velez Van Meerbeke; Claudia Alejandra López Cabra; Paula Marcela Herrera Gomez
Journal:  Front Pediatr       Date:  2017-10-30       Impact factor: 3.418

4.  Attention Deficit Predicts Intellectual Functioning in Children with Neurofibromatosis Type 1.

Authors:  Magdalena Heimgärtner; Sofia Granström; Karin Haas-Lude; Robert A Leark; Victor-Felix Mautner; Karen Lidzba
Journal:  Int J Pediatr       Date:  2019-12-10

5.  Psychometric Properties of Attention Measures in Young Children with Neurofibromatosis Type 1: Preliminary Findings.

Authors:  Sara K Pardej; Kristin M Lee; Danielle M Glad; Bonita P Klein-Tasman
Journal:  J Pediatr Neuropsychol       Date:  2022-08-23

6.  The Effect of Long-Acting Methylphenidate and Modafinil on Attention and Impulsivity of Children with ADHD using a Continuous Performance Test: A Comparative Study.

Authors:  Ghazal Zahed; Maliheh Roozbakhsh; Rozita Davari Ashtiani; Katayoun Razjouyan
Journal:  Iran J Child Neurol       Date:  2022-07-16

7.  The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.

Authors:  Francesca Cervi; Veronica Saletti; Katherine Turner; Angela Peron; Sara Bulgheroni; Matilde Taddei; Francesca La Briola; Maria Paola Canevini; Aglaia Vignoli
Journal:  Orphanet J Rare Dis       Date:  2020-09-07       Impact factor: 4.123

8.  Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.

Authors:  Natalie A Pride; Belinda Barton; Paul Hutchins; David R Coghill; Mayuresh S Korgaonkar; Stephen J C Hearps; Melissa Rouel; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692

9.  Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model.

Authors:  J L Lukkes; H P Drozd; S D Fitz; A I Molosh; D W Clapp; A Shekhar
Journal:  J Neurodev Disord       Date:  2020-01-15       Impact factor: 4.025

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.